liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic-ischemic brain injury.
Perinatal Center, University of Gothenburg, Gothenburg, Sweden.
Centre for the Developing Brain, King's College, London, UK.
Center for Brain Repair and Rehabilitation, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Center for Brain Repair and Rehabilitation, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Show others and affiliations
2013 (English)In: The FASEB Journal, ISSN 0892-6638, E-ISSN 1530-6860, Vol. 27, no 9, 3797-3804 p.Article in journal (Refereed) Published
Abstract [en]

Complement is an essential component of inflammation that plays a role in ischemic brain injury. Recent reports demonstrate novel functions of complement in normal and diseased CNS, such as regulation of neurogenesis and synapse elimination. Here, we examined the role of complement-derived peptide C3a in unilateral hypoxia-ischemia (HI), a model of neonatal HI encephalopathy. HI injury was induced at postnatal day 9 (P9), and loss of hippocampal tissue was determined on P31. We compared WT mice with transgenic mice expressing C3a under the control of glial fibrillary acidic protein promoter, which express biologically active C3a only in CNS and without the requirement of a priori complement activation. Further, we injected C3a peptide into the lateral cerebral ventricle of mice lacking the C3a receptor (C3aR) and WT mice and assessed HI-induced memory impairment 41 d later. We found that HI-induced tissue loss in C3a overexpressing mice was reduced by 50% compared with WT mice. C3a peptide injected 1 h after HI protected WT but not C3aR-deficient mice against HI-induced memory impairment. Thus, C3a acting through its canonical receptor ameliorates behavioral deficits after HI injury, and C3aR is a novel therapeutic target for the treatment of neonatal HI encephalopathy.

Place, publisher, year, edition, pages
Bethesda: Federation of American Societies for Experimental Biology , 2013. Vol. 27, no 9, 3797-3804 p.
National Category
Basic Medicine
Identifiers
URN: urn:nbn:se:liu:diva-132793DOI: 10.1096/fj.13-230011PubMedID: 23737250OAI: oai:DiVA.org:liu-132793DiVA: diva2:1049736
Available from: 2016-11-25 Created: 2016-11-25 Last updated: 2016-11-29Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Atkins, Alison Lynn
By organisation
Division of Cell BiologyFaculty of Medicine and Health Sciences
In the same journal
The FASEB Journal
Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 5 hits
ReferencesLink to record
Permanent link

Direct link